TCM
SUPN icon

Tekla Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Tekla Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-140,800
Closed -$1.26M – 66
2014
Q1 		$1.26M Hold
140,800
– – 0.13% 58
2013
Q4 		$1.06M Hold
140,800
– – 0.11% 54
2013
Q3 		$1.03M Hold
140,800
– – 0.11% 60
2013
Q2 		$905K Buy
+140,800
New +$829K 0.12% 56

Other funds holding SUPN

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
MRM
Michael R. Murphy $255M AUM 0.87% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
OHCM
Orchard Hill Capital Management New York $22.6M AUM 3.52% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return

Tekla Capital Management's SUPN Position: Q2 2014 in Review

Tekla Capital Management sold out of Supernus Pharmaceuticals (SUPN) in Q2 2014, closing a stake of 140,800 shares — an estimated $1.26M sold.

Tekla Capital Management first reported a position in SUPN in Q2 2013 and held it in 4 quarters. The position peaked at $1.26M in Q1 2014. 88 funds tracked by Wall St. Rank hold SUPN as of Q2 2014.

  • Tekla Capital Management reported no remaining Supernus Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • Tekla Capital Management sold 140,800 Supernus Pharmaceuticals shares in Q2 2014, an estimated $1.26M.
  • Tekla Capital Management first reported a position in Supernus Pharmaceuticals in Q2 2013 and held it in 4 quarters.
  • Tekla Capital Management's Supernus Pharmaceuticals position peaked at $1.26M in Q1 2014.
  • 88 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2014.

Based on Tekla Capital Management's 13F filing for Q2 2014, filed 5 Aug 2014.